

Appointment of CMO – Professor John Olynyk

Highlights

- Professor John Olynyk appointed Chief Medical Officer (CMO) of Resonance Health
- Dean of Clinical Research & Professor of Translational Medicine, Edith Cowan University
- Theme Lead-Health Research, Edith Cowan University (former Prof. St Louis University, USA)
- Consultant Hepatologist at Fiona Stanley Hospital (Head of Gastroenterology, 2015-2020)
- Medical advisor to Haemochromatosis Australia, Consultant to Red Cross Lifeblood (Aust)
- Fellow of American Assoc for Study of Liver Disease, and American Gastroenterology Assoc
- Over 250 articles and 180 conference abstracts published on liver related diseases

Appointment of Chief Medical Officer

Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to advise that Prof. John Olynyk has been appointed Chief Medical Officer (“CMO”). Prof. Olynyk is an internationally recognised leader in liver-related diseases including iron-metabolism disorders, hemochromatosis, liver-injury, hepatocellular carcinoma, and non-alcoholic fatty liver disease (“NAFLD”).

Prof. Olynyk’s current roles include consultant Hepatologist in the Dept of Gastroenterology at Fiona Stanley Hospital (formerly Head of Gastroenterology, 2015-2020), Dean of Clinical Research & Professor of Translational Medicine at ECU, Theme Lead of Health Research at ECU, Member of the Joint Scientific Committee of Haemochromatosis International, and Medical Advisor to both Haemochromatosis Australia and Red Cross Lifeblood Australia.

Over the course of his career Prof. Olynyk has contributed to over 250 published articles, 180 conference abstracts, and has authored 11 book chapters and miscellaneous publications including on the topics of iron in chronic liver disease, iron overload, and brain changes in iron loading disorders. He has also spoken and presented by invitation at dozens of international and national conferences related to liver diseases.

Prof. Olynyk has won several awards and grants for research projects and is currently involved in several projects and trials that tie closely to the Company’s products and services and its core expertise in the liver and iron-related diseases. He will play a key role as a consultant in guiding the Company’s rollout of products and services and in assisting relations with international clinical key opinion leaders and disease advocacy groups in diseases related to the Company’s products.

He will also host and lead clinical educational seminars including webinars and educational posts on diseases that may benefit from the Company’s suite of products and services and he will help guide product development and evolution to ensure it best meets the needs of clinicians. Prof. Olynyk studied medicine and surgery at the University of Western Australia in the 1980s before becoming an accredited Gastroenterologist in 1991.

CMO of Resonance Health, Prof. John Olynyk commented:

“Liver diseases are unfortunately on the rise, and we are seeing an explosion of fatty-liver related health complications globally, including in developed nations where obesity and unhealthy diets are causing a range of long-term liver-related health complications.

Like most clinicians that work in liver-related diseases I am aware of Resonance Health’s products and services including its FerriScan® product which is considered the gold standard for diagnosing and measuring liver-iron-concentration, and HepaFat-Scan® which measures and maps liver fat content, providing a quantitative score, allowing clinicians and patients to track the severity of hepatic fat content.

With the alarming and currently unchecked growth in liver-diseases and the advent of credible scientific research pointing to linkages between nonalcoholic fatty liver disease and global endemic problems such as the metabolic syndrome comprising diabetes mellitus, hypertension, elevated blood triglycerides and obesity, Resonance Health is well positioned to respond to these health challenges and to provide solutions for clinicians and patients.

It is pleasing to see the Company evolving its products and services through the adaptation of AI and this should greatly assist the rollout of Resonance Health’s products and services to a broader global audience, including to parts of the world where the manual analysis services provided by Resonance Health are unaffordable. Fatty-liver related diseases are a significant problem in several large emerging markets including in India and Middle Eastern nations.

I am excited to work with Resonance Health for the benefit of patients, clinicians, and the Company and its shareholders, and I look forward to making a meaningful contribution to all stakeholders. There is much work to be done in educating all stakeholders about the perils of liver disease and I am confident that with the right clinical education and engagement, and technology implementation strategies, Resonance Health will prosper.”

Managing Director of Resonance Health, Mitchell Wells commented:

“In the short time we have known Professor Olynyk we have learnt much more about the disease states that are most closely related to our core products and services, and how we can help. Having a world-renowned clinical-medical expert as part of our team, to educate and guide, and to engage with clinicians as required, is a critical piece of the puzzle that we have sought to solve.

It is fortuitous that Prof. Olynyk is based in Perth near our head office, and we are pleased to be able to leverage Prof. Olynyk’s experience and relationships with key opinion leaders globally, for the benefit of patients and clinicians that are contending with liver-related diseases. Prof. Olynyk and his colleagues are also involved in studies and research relevant to Resonance Health and we look forward to supporting this important work, including by the provision of our products and services.”

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd.

For further information please contact:

Mitchell Wells

Managing Director, Resonance Health Ltd

E: mitchellw@resonancehealth.com

P: +61 (0)8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company, specialising in the development and delivery of noninvasive medical imaging software and services.

The Company's products are used globally by clinicians in the diagnosis and management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for consistently providing high quality quantitative measurements essential in the diagnosis and management of diseases.

Resonance Health's dedication to scientific rigour and quality management has enabled it to achieve regulatory clearances for a range of Software as a Medical Device (**SaMD**) products in the USA, Europe, and Australia and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Some of the SaMD products incorporate the use of Artificial Intelligence (**AI**):

- **FerriScan**[®] - provides an accurate measurement of liver iron concentration (**LIC**) through a non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. FerriScan[®] is internationally recognised as the gold standard in LIC assessment.
- **FerriSmart**[®] - an AI-driven system for the automated real-time measurement of LIC in patients using non-invasive MRI-based technology.
- **HepaFat-AI**[®] - an AI-driven system for the automated real-time multi-metric measurement of liver fat in patients using non-invasive MRI-based technology, for use in the assessment of individuals with confirmed or suspected fatty liver disease.
- **CardiacT2*** – the most widely accepted MRI based method for assessing heart iron loading. Resonance Health also offers a dual analysis of FerriScan and CardiacT2*. CardiacT2* has regulatory clearance from the FDA, TGA and CE Mark.

The Company has an active development pipeline of additional medical imaging analysis products and services, including, **LiverSmart**[™] and **Alert-PE**[™], an AI tool for the automated review of chest CT scans of patients with suspected pulmonary embolism.